Dyskinesias and neural grafting in Parkinson's disease

Restorative Therapies in Parkinson's Disease

Volumn , Issue , 2006, Pages 184-224

  Cenci Nilsson, M Angela ^a   Hagell, Peter ^b,c  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84900193923     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/0-387-32823-2_10     Document Type: Chapter

References (165)

1. Abercrombie, E. D., Bonatz, A. E., Zigmond, M. J. (1990) Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine- treated rats. Brain Res 525:36-44.
2. Ahlskog, J. E., Muenter, M. D. (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature.Mov Disord 16: 448-458.
3. Aichner, F., Adelwohrer, C., Haring, H. P. (2002) Rehabilitation approaches to stroke. J Neural Transm Suppl: 59-73.
4. Andersson, M., Hilbertson, A., Cenci, M. A. (1999) Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol Dis 6:461-474.
5. Andersson, M., Konradi, C., Cenci, M. A. (2001) cAMP response element-binding protein is required for dopamine-dependent gene expression in the intact but not the dopamine-denervated striatum. J Neurosci 21:9930-9943.
6. Barker, R. A. (2000) Prospects for the treatment of Parkinson's disease using neural grafts. Expert Opin Pharmacother 1:889-902.
7. Barker, R. A., Dunnett, S. B., Faissner, A., Fawcett, J. W. (1996) The time course of loss of dopaminergic neurons and the gliotic reaction surrounding grafts of embryonic mesencephalon to the striatum. Exp Neurol 141: 79-93.
8. Bedard, P. J., Blanchet, P. J., Levesque, D., Soghomonian, J. J., Grondin, R., Morissette, M., Goulet, M., Calon, F., Falardeau, P., Gomez-Mancilla, B., Doucet, J. P., Robertson, G. S., DiPaolo, T. (1999) Pathophysiology of L-dopa-induced dyskinesias. Mov Disord 14 Suppl 1:4-8.
9. Bhatia, K. P., Marsden, C. D. (1994) The behavioural and motor consequences of focal lesions of the basal ganglia in man. Brain 117:859-876.
10. Björklund, A. (1992) Dopaminergic transplants in experimental parkinsonism: cellular mechanisms of graft-induced functional recovery. Curr Opin Neurobiol 2:683-689.
11. Björklund, A., Stenevi, U. (1979) Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants. Brain Res 177:555-560.
12. Blanchard, V., Raisman-Vozari, R., Vyas, S., Michel, P. P., Javoy-Agid, F., Uhl, G., Agid, Y. (1994) Differential expression of tyrosine hydroxylase and membrane dopamine transporter genes in subpopulations of dopaminergic neurons of the rat mesencephalon. Brain Res Mol Brain Res 22: 29-38.
13. Boesch, S. M., Wenning, G. K., Ransmayr, G., Poewe, W. (2002) Dystonia in multiple system atrophy. J Neurol Neurosurg Psychiatry 72:300-303.
14. Bolam, J. P., Freund, T. F., Björklund, A., Dunnett, S. B., Smith, A. D. (1987) Synaptic input and local output of dopaminergic neurons in grafts that functionally reinnervate the host neostriatum. Exp Brain Res 68:131-146.
15. Brooks, D. Parkinson's disease: New insights from functional imaging (The Stanley Fahn Lecture). 7th Int. Congress of Parkinson's Disease and Movement Disorders, Miami, FL, 2002.
16. Brundin, P., Pogarell, O., Hagell, P., Piccini, P., Widner, H., Schrag, A., Kupsch, A., Crabb, L., Odin, P., Gustavii, B., Björklund, A., Brooks, D. J., Marsden, C. D., Oertel, W. H., Quinn, N. P., Rehncrona, S., Lindvall, O. (2000) Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. Brain 123 (Pt 7):1380-1390.
17. Burns, L. H., Pakzaban, P., Deacon, T.W., Brownell, A. L., Tatter, S. B., Jenkins, B. G., Isacson, O. (1995) Selective putaminal excitotoxic lesions in non-human primates model the movement disorder of Huntington disease. Neuroscience 64:1007-1017.
18. Calon, F., Hadj Tahar, A., Blanchet, P. J., Morissette, M., Grondin, R., Goulet, M., Doucet, J. P., Robertson, G. S., Nestler, E., Di Paolo, T., Bedard, P. J. (2000) Dopamine-receptor stimulation: biobehavioral and biochemical consequences. Trends Neurosci 23:S92-100.
19. Carlsson, T.,Winkler, C., Lundblad, M., Cenci, M.A., Björklund, A., Kirik, D. (2005) Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia. Neurobiol Dis. Oct 24; [Epub ahead of print] PMID: 16256359 [PubMed-as supplied by publisher).
20. Carvey, P. M., Lin, D. H., Faselis, C. J., Notermann, J. K., Ling, Z. D. (1996) Loss of striatal DA innervation increases striatal trophic activity directed at DA neurons in culture. Exp Neurol 140:184-197.
21. Cenci, A. M., Andersson, M., Daniel, S. E., Kingsbury, A. E., Kilford, L., Lees, A. J. (2002) Striatal expression of FosB-related transcription factors in human Parkinson's disease: Relation to L-dopa-induced dyskinesias. Movement Disorders 17:S98.
22. Cenci, M. A., Björklund, A. (1994) Transection of corticostriatal afferents abolishes the hyperexpression of Fos and counteracts the development of rotational overcompensation induced by intrastriatal dopamine-rich grafts when challenged with amphetamine. Brain Res 665:167-174.
23. Cenci, M. A., Campbell, K., Björklund, A. (1993) Neuropeptide messenger RNA expression in the 6-hydroxydopamine-lesioned rat striatum reinnervated by fetal dopaminergic transplants: differential effects of the grafts on preproenkephalin, preprotachykinin and prodynorphin messenger RNA levels. Neuroscience 57:275-296.
24. Cenci, M. A., Campbell, K., Björklund, A. (1997) Glutamic acid decarboxylase gene expression in the dopamine-denervated striatum: effects of intrastriatal fetal nigral transplants or chronic apomorphine treatment. Brain Res Mol Brain Res 48:149-155.
25. Cenci, M. A., Kalen, P., Duan, W. M., Björklund, A. (1994) Transmitter release from transplants of fetal ventral mesencephalon or locus coeruleus in the rat frontal cortex and nucleus accumbens: effects of pharmacological and behaviorally activating stimuli. Brain Res 641:225-248.
26. Cenci, M. A., Kalen, P., Mandel, R. J., Björklund, A. (1992a) Regional differences in the regulation of dopamine and noradrenaline release in medial frontal cortex, nucleus accumbens and caudate-putamen: a microdialysis study in the rat. Brain Res 581:217-228.
27. Cenci, M. A., Kalen, P., Mandel, R. J., Wictorin, K., Björklund, A. (1992b) Dopaminergic transplants normalize amphetamine-and apomorphine-induced Fos expression in the 6-hydroxydopamine-lesioned striatum. Neuroscience 46:943-957.
28. Cenci, M. A., Lee, C. S., Björklund, A. (1998) L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin-and glutamic acid decarboxylase mRNA. Eur J Neurosci 10:2694-2706.
29. Chase, T. N. (1998) Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology 50:S17-25.
30. Chritin, M., Savasta, M., Mennicken, F., Bal, A., Abrous, D. N., Le Moal, M., Feuerstein, C., Herman, J. P. (1992) Intrastriatal Dopamine-rich Implants Reverse the Increase of Dopamine D2 Receptor mRNA Levels Caused by Lesion of the Nigrostriatal Pathway: A Quantitative In Situ Hybridization Study. Eur J Neurosci 4:663-672.
31. Clarke, D. J., Brundin, P., Strecker, R. E., Nilsson, O. G., Björklund, A., Lindvall, O. (1988) Human fetal dopamine neurons grafted in a rat model of Parkinson's disease: ultrastructural evidence for synapse formation using tyrosine hydroxylase immunocytochemistry. Exp Brain Res 73:115-126.
32. Colzi, A., Turner, K., Lees, A. J. (1998) Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry 64:573-576.
33. Cowan, W. M., Kandel, E. R. (2001) Prospects for neurology and psychiatry. JAMA 285:594-600.
34. Cragg, S. J., Clarke, D. J., Greenfield, S. A. (2000) Real-time dynamics of dopamine released from neuronal transplants in experimental Parkinson's disease. Exp Neurol 164:145-153.
35. Cragg, S. J., Hille, C. J., Greenfield, S. A. (2002) Functional domains in dorsal striatum of the nonhuman primate are defined by the dynamic behavior of dopamine. J Neurosci 22:5705-5712.
36. Cubo, E., Gracies, J. M., Benabou, R., Olanow, C. W., Raman, R., Leurgans, S., Goetz, C. G. (2001) Early morning off-medication dyskinesias, dystonia, and choreic subtypes. Arch Neurol 58:1379-1382.
37. Dahlström, A., Fuxe, K. (1964) Evidence for the existence of monoamine-containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta Physiol. Scand. 62:1-55.
38. Darnell, J. E., Jr., Kerr, I. M., Stark, G. R. (1994) Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415-1421.
39. Dawson, T. M., Dawson, V. L., Gage, F. H., Fisher, L. J., Hunt, M. A., Warmsley, J. K. (1991) Functional recovery of supersensitive dopamine receptors after intrastriatal grafts of fetal substantia nigra. Expl. Neurol. 111:282-292.
40. de la Fuente-Fernandez, R., Stoessl, A. J. (2002) Parkinson's disease: imaging update. Curr Opin Neurol 15:477-482.
41. Defer, G. L., Geny, C., Ricolfi, F., Fenelon, G., Monfort, J. C., Remy, P., Villafane, G., Jeny, R., Samson, Y., Keravel, Y., Gaston, A., Degos, J. D., Peschanski, M., Cesaro, P., Nguyen, J. P. (1996) Long-term outcome of unilaterally transplanted parkinsonian patients. I. Clinical approach. Brain 119 (Pt 1):41-50.
42. Defer, G. L.,Widner, H., Marie, R. M., Remy, P., Levivier, M. (1999) Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD). Mov Disord 14:572-584.
43. Doucet, G., Brundin, P., Descarries, L., Björklund, A. (1990) Effect of Prior Dopamine Denervation on Survival and Fiber Outgrowth from Intrastriatal Fetal Mesencephalic Grafts. Eur J Neurosci 2:279-290.
44. Doucet, G., Murata, Y., Brundin, P., Bosler, O., Mons, N., Geffard, M., Ouimet, C. C., Björklund, A. (1989) Host afferents into intrastriatal transplants of fetal ventral mesencephalon. Exp Neurol 106:1-19.
45. Doucet, J. P., Nakabeppu, Y., Bedard, P. J., Hope, B. T., Nestler, E. J., Jasmin, B. J., Chen, J. S., Iadarola, M. J., St-Jean, M., Wigle, N., Blanchet, P., Grondin, R., Robertson, G. S. (1996) Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum. Eur J Neurosci 8:365-381.
46. Durif, F., Vidailhet, M., Debilly, B., Agid, Y. (1999) Worsening of levodopa-induced dyskinesias by motor and mental tasks. Mov Disord 14:242-245.
47. Engber, T. M., Susel, Z., Kuo, S., Chase, T. N. (1990) Chronic levodopa treatment alters basal and dopamine agonist-stimulated cerebral glucose utilization. J Neurosci 10:3889-3895.
48. Facca, A., Sanchez-Ramos, J. (1996) High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias. Mov Disord 11:327-329.
49. Fahn, S. 1992. Adverse effects of levodopa. In Olanow, C.W, Lieberman, A. N. (eds.); The Scientific Basis for the Treatment of Parkinson's Disease. pp. 89-112. Parthenon Publishing Group, London, pp. 89-112.
50. Fahn, S., Elton, R. L., Committee, m. o. t. U. D. 1987. Unified Parkinson's Disease Rating Scale. In Fahn, S., Marsden, C. D., Calne, D. B., and Goldstein, M. (eds.): Recent Developments in Parkinson's Disease, Vol. 2. MacMillan Healthcare Information, Florham Park, pp. 153-163.
51. Fawcett, J. W., Barker, R. A., Dunnett, S. B. (1995) Dopaminergic neuronal survival and the effects of bFGF in explant, three dimensional and monolayer cultures of embryonic rat ventral mesencephalon. Exp Brain Res 106:275-282.
52. Forni, C., Brundin, P., Strecker, R. E., el Ganouni, S., Björklund, A., Nieoullon, A. (1989) Time-course of recovery of dopamine neuron activity during reinnervation of the denervated striatum by fetal mesencephalic grafts as assessed by in vivo voltammetry. Exp Brain Res 76:75-87.
53. Freed, C. R., Breeze, R. E., Rosenberg, N. L., Schneck, S. A., Kriek, E., Qi, J. X., Lone, T., Zhang, Y. B., Snyder, J. A.,Wells, T. H., et al. (1992) Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. N Engl J Med 327:1549-1555.
54. Freed, C. R., Greene, P. E., Breeze, R. E., Tsai, W. Y., DuMouchel, W., Kao, R., Dillon, S., Winfield, H., Culver, S., Trojanowski, J. Q., Eidelberg, D., Fahn, S. (2001) Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 344:710-719.
55. Freund, T. F., Bolam, J. P., Björklund, A., Stenevi, U., Dunnett, S. B., Powell, J. F., Smith, A. D. (1985) Efferent synaptic connections of grafted dopaminergic neurons reinnervating the host neostriatum: a tyrosine hydroxylase immunocytochemical study. J Neurosci 5:603-616.
56. Freund, T. F., Powell, J. F., Smith, A. D. (1984) Tyrosine hydroxylase-immunoreactive boutons in synaptic contact with identified striatonigral neurons, with particular reference to dendritic spines. Neuroscience 13:1189-1215.
57. Fricker-Gates, R. A., Lundberg, C., Dunnett, S. B. (2001) Neural transplantation: restoring complex circuitry in the striatum. Restor Neurol Neurosci 19:119-138.
58. Gage, F. H., Brundin, P., Strecker, R., Dunnett, S. B., Isacson, O., Björklund, A. (1988) Intracerebral neuronal grafting in experimental animal models of agerelated motor dysfunction. Ann N Y Acad Sci 515:383-394.
59. Gagnon, C., Bedard, P. J., Rioux, L., Gaudin, D., Martinoli, M. G., Pelletier, G., Di Paolo, T. (1991) Regional changes of striatal dopamine receptors following denervation by 6-hydroxydopamine and fetal mesencephalic grafts in the rat. Brain Res 558:251-263.
60. Gerfen, C. R., Engber, T. M., Mahan, L. C., Susel, Z., Chase, T. N., Monsma, F. J., Jr., Sibley, D. R. (1990) D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250:1429-1432.
61. Gimenez-Roldan, S., Mateo, D. (1989) [Huntington disease: tetrabenazine compared to haloperidol in the reduction of involuntary movements]. Neurologia 4:282-287.
62. Goetz, C. G. (1999) Rating scales for dyskinesias in Parkinson's disease. Mov Disord 14 Suppl 1:48-53.
63. Goetz, C. G., Stebbins, G. T., Blasucci, L. M., Grobman, M. S. (1997) Efficacy of a patient-training videotape on motor fluctuations for on-off diaries in Parkinson's disease. Mov Disord 12:1039-1041.
64. Greene, P. E., Fahn, S., Tsai, W. Y., Breeze, R. E., Eidelberg, D., Winfield, H., Dillon, S., Kao, R.,Winfield, L., Freed, C. R. (1999) Severe spontaneous dyskinesias: a disabling complication of embryonic dopaminergic tissue implants in a subset of transplanted patients with advanced Parkinson's disease. Movement Disorders 14:904.
65. Grisolia, J. S. (2002) CNS stem cell transplantation: clinical and ethical perspectives. Brain Res Bull 57:823-826.
66. Guy, W. 1976. ECDEU assessment manual. Department of Health, Education and Welfare, Rockville.
67. Hagell, P., Brundin, P. (2001) Cell survival and clinical outcome following intrastriatal transplantation in Parkinson disease. J Neuropathol Exp Neurol 60:741-752.
68. Hagell, P., Piccini, P., Björklund, A., Brundin, P., Rehncrona, S., Widner, H., Crabb, L., Pavese, N., Oertel, W. H., Quinn, N., Brooks, D. J., Lindvall, O. (2002) Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci 5:627-628.
69. Hagell, P., Schrag, A., Piccini, P., Jahanshahi, M., Brown, R., Rehncrona, S., Widner, H., Brundin, P., Rothwell, J. C., Odin, P.,Wenning, G. K., Morrish, P., Gustavii, B., Björklund, A., Brooks, D. J., Marsden, C. D., Quinn, N. P., Lindvall, O. (1999) Sequential bilateral transplantation in Parkinson's disease: effects of the second graft. Brain 122 ( Pt 6):1121-1132.
70. Hagell, P., Widner, H. (1999) Clinical rating of dyskinesias in Parkinson's disease: use and reliability of a new rating scale. Mov Disord 14:448-455.
71. Hantraye, P., Riche, D., Maziere, M., Isacson, O. (1990) A primate model of Huntington's disease: behavioral and anatomical studies of unilateral excitotoxic lesions of the caudate-putamen in the baboon. Exp Neurol 108:91-104.
72. Haque, N. S., LeBlanc, C. J., Isacson, O. (1997) Differential dissection of the rat E16 ventral mesencephalon and survival and reinnervation of the 6-OHDA-lesioned striatum by a subset of aldehyde dehydrogenase-positive TH neurons. Cell Transplant 6:239-248.
73. Hauser, R. A., Freeman, T. B., Snow, B. J., Nauert, M., Gauger, L., Kordower, J. H., Olanow, C.W. (1999) Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch Neurol 56:179-187.
74. Herman, J. P., Abrous, N. D. (1994) Dopaminergic neural grafts after fifteen years: results and perspectives. Prog Neurobiol 44:1-35.
75. Hisanaga, K., Sagar, S. M., Sharp, F. R. (1992) C-fos induction occurs in cultured cortical neurons and astrocytes via multiple signaling pathways. Prog Brain Res 94: 189-195.
76. Hoglinger, G. U., Sautter, J., Meyer, M., Spenger, C., Seiler, R. W., Oertel, W. H., Widmer, H. R. (1998) Rat fetal ventral mesencephalon grown as solid tissue cultures: influence of culture time and BDNF treatment on dopamine neuron survival and function. Brain Res 813:313-322.
77. Hoglinger, G. U.,Widmer, H. R., Spenger, C., Meyer, M., Seiler, R.W., Oertel,W. H., Sautter, J. (2001) Influence of time in culture and BDNF pretreatment on survival and function of grafted embryonic rat ventral mesencephalon in the 6-OHDA rat model of Parkinson's disease. Exp Neurol 167:148-157.
78. Hopkins, S. J., Rothwell, N. J. (1995) Cytokines and the nervous system. I: Expression and recognition. Trends Neurosci 18:83-88.
79. Huang, Z., de la Fuente-Fernandez, R., Hauser, R. A., Freeman, T. B., Sossi, V., Olanow, C.W., Stoessl, J. A. (2003) Dopaminergic alteration in Parkinson's patients with off-period dyskinesia following striatal embryonic mesencephalic transplant. Neurology 60:A126.
80. Hufford, M. R., Shiffman, S. (2002) Methodological issues affecting the value of patient-reported outcomes data. Expert Review of Pharmacoeconomics and Outcomes Research 2:119-128.
81. Isacson, O., Björklund, L. M., Schumacher, J. M. (2003) Toward full restoration of synaptic and terminal function of the dopaminergic system in Parkinson's disease by stem cells. Ann Neurol 53 Suppl 3:S135-146; discussion S146-138.
82. Jacques, D. B., Kopyov, O. V., Eagle, K. S., Carter, T., Lieberman, A. (1999) Outcomes and complications of fetal tissue transplantation in Parkinson's disease. Stereotact Funct Neurosurg 72:219-224.
83. Jaeger, C. B. (1985) Cytoarchitectonics of substantia nigra grafts: a light and electron microscopic study of immunocytochemically identified dopaminergic neurons and fibrous astrocytes. J Comp Neurol 231:121-135.
84. Jankovic, J., Tintner, R. (2001) Dystonia and parkinsonism. Parkinsonism Relat Disord 8:109-121.
85. Juncos, J. L., Engber, T. M., Raisman, R., Susel, Z., Thibaut, F., Ploska, A., Agid, Y., Chase, T. N. (1989) Continuous and intermittent levodopa differentially affect basal ganglia function. Ann Neurol 25:473-478.
86. Kirik, D.,Winkler, C., Björklund, A. (2001) Growth and functional efficacy of intrastriatal nigral transplants depend on the extent of nigrostriatal degeneration. J Neurosci 21:2889-2896.
87. Kish, S. J., Shannak, K., Hornykiewicz, O. (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 318:876-880.
88. Klawans, H. L., Goetz, C., Nausieda, P. A., Weiner, W. J. (1977) Levodopa-induced dopamine receptor hypersensitivity. Trans Am Neurol Assoc 102:80-83.
89. Kolata, G. (2001) Parkinson's disease is set back by failure of fetal cell implants. NY Times 8 march:381.
90. Konitsiotis, S., Blanchet, P. J., Verhagen, L., Lamers, E., Chase, T. N. (2000) AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology 54:1589-1595.
91. Kopyov, O. V., Jacques, D., Lieberman, A., Duma, C. M., Rogers, R. L. (1996) Clinical study of fetal mesencephalic intracerebral transplants for the treatment of Parkinson's disease. Cell Transplant 5:327-337.
92. Kopyov, O. V., Jacques, D. S., Lieberman, A., Duma, C. M., Rogers, R. L. (1997) Outcome following intrastriatal fetal mesencephalic grafts for Parkinson's patients is directly related to the volume of grafted tissue. Exp Neurol 146:536-545.
93. Kordower, J. H., Rosenstein, J. M., Collier, T. J., Burke, M. A., Chen, E. Y., Li, J. M., Martel, L., Levey, A. E., Mufson, E. J., Freeman, T. B., Olanow, C. W. (1996) Functional fetal nigral grafts in a patient with Parkinson's disease: chemoanatomic, ultrastructural, and metabolic studies. J Comp Neurol 370:203-230.
94. Kordower, J. H., Styren, S., Clarke, M., DeKosky, S. T., Olanow, C. W., Freeman, T. B. (1997) Fetal grafting for Parkinson's disease: expression of immune markers in two patients with functional fetal nigral implants. Cell Transplantation 6:213-219.
95. Kostic, V. S., Marinkovic, J., Svetel, M., Stefanova, E., Przedborski, S. (2002) The effect of stage of Parkinson's disease at the onset of levodopa therapy on development of motor complications. Eur J Neurol 9:9-14.
96. Lane, E. L.,Winkler, C., Brundin, P., Cenci, M. A. (2006) The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat. Neurobiol Dis. Jan 5; [Epub ahead of print] PMID: 16406222 [PubMed-as supplied by publisher]
97. Langston, J. W., Widner, H., Goetz, C. G., Brooks, D., Fahn, S., Freeman, T., Watts, R. (1992) Core assessment program for intracerebral transplantations (CAPIT). Mov Disord 7:2-13.
98. Lanska, D. J. (2000) George Huntington (1850-1916) and hereditary chorea. J Hist Neurosci 9:76-89.
99. Lee, C. S., Cenci, M. A., Schulzer, M., Björklund, A. (2000) Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease. Brain 123 ( Pt 7):1365-1379.
100. Levivier, M., Dethy, S., Rodesch, F., Peschanski, M., Vandesteene, A., David, P.,Wikler, D., Goldman, S., Claes, T., Biver, F., Liesnard, C., Goldman, M., Hildebrand, J., Brotchi, J. (1997) Intracerebral transplantation of fetal ventral mesencephalon for patients with advanced Parkinson's disease. Methodology and 6-month to 1-year follow-up in 3 patients. Stereotact Funct Neurosurg 69:99-111.
101. Lhermitte, F., Agid, Y., Signoret, J. L. (1978) Onset and end-of-dose levodopainduced dyskinesias. Possible treatment by increasing the daily doses of levodopa. Arch Neurol 35:261-263.
102. Lindvall, O. 1994. Neural transplantation in Parkinson's disease. In (Dunnett, S. B., and Björklund, A. (Eds.); Functional Neural Transplantation. Raven Press, Ltd., New York, pp. 103-137.
103. Lindvall, O., Björklund, A. (1992) Intracerebral grafting of inhibitory neurons. A new strategy for seizure suppression in the central nervous system. Adv Neurol 57:561-569.
104. Lindvall, O., Hagell, P. (2000) Clinical observations after neural transplantation in Parkinson's disease. Prog Brain Res 127:299-320.
105. Lovinger, D. M., Tyler, E. (1996) Synaptic transmission and modulation in the neostriatum. Int Rev Neurobiol 39:77-111.
106. Luquin, M. R., Scipioni, O., Vaamonde, J., Gershanik, O., Obeso, J. A. (1992) Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Mov Disord 7:117-124.
107. Ma, Y., Feigin, A., Dhawan, V., Fukuda, M., Shi, Q., Greene, P., Breeze, R., Fahn, S., Freed, C., Eidelberg, D. (2002) Dyskinesia after fetal cell transplantation for parkinsonism: a PET study. Ann Neurol 52:628-634.
108. Mahalik, T. J., Finger, T. E., Stromberg, I., Olson, L. (1985) Substantia nigra transplants into denervated striatum of the rat: ultrastructure of graft and host interconnections. J Comp Neurol 240:60-70.
109. Marconi, R., Lefebvre-Caparros, D., Bonnet, A. M., Vidailhet, M., Dubois, B., Agid, Y. (1994) Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology. Mov Disord 9:2-12.
110. Maries, E., Kordower, J.H., Chu, Y., Collier, T.J., Sortwell, C.E., Olaru, E., Shannon, K., Steece-Collier, K. (2005) Focal not widespread grafts induce novel dyskinetic behavior in parkinsonian rats. Neurobiol Dis, in press
111. Marsden, C. D., Parkes, J. D., Quinn, N. (1981) Fluctuations in disability in Parkinson's disease-clinical aspects. In Movement Disorders (C. D. Marsden, and S. Fahn, Eds.), pp. 96-122. Butterworths, London.
112. Mendez, I., Dagher, A., Hong, M., Hebb, A., Gaudet, P., Law, A., Weerasinghe, S., King, D., Desrosiers, J., Darvesh, S., Acorn, T., Robertson, H. (2000) Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line-derived neurotrophic factor in patients with Parkinson's disease. Report of two cases and technical considerations. J Neurosurg 92:863-869.
113. Miller, D. W., Abercrombie, E. D. (1999) Role of high-affinity dopamine uptake and impulse activity in the appearance of extracellular dopamine in striatum after administration of exogenous L-DOPA: studies in intact and 6-hydroxydopaminetreated rats. J Neurochem 72:1516-1522.
114. Mishra, R. K., Marshall, A. M., Varmuza, S. L. (1980) Supersensitivity in rat caudate nucleus: effects of 6-hydroxydopamine on the time course of dopamine receptor and cyclic AMP changes. Brain Res 200:47-57.
115. Morissette, M., Grondin, R., Goulet, M., Bedard, P. J., Di Paolo, T. (1999) Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists. J Neurochem 72:682-692.
116. Morrish, P. K., Sawle, G. V., Brooks, D. J. (1996) An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 119 ( Pt 2):585-591.
117. Moukhles, H., Forni, C., Nieoullon, A., Daszuta, A. (1994) Regulation of dopamine levels in intrastriatal grafts of fetal mesencephalic cell suspension: an in vivo voltammetric approach. Exp Brain Res 102:10-20.
118. Niimi, M., Sato, M., Wada, Y., Takahara, J., Kawanishi, K. (1996) Effect of central and continuous intravenous injection of interleukin-1 beta on brain c-fos expression in the rat: involvement of prostaglandins. Neuroimmunomodulation 3:87-92.
119. Niimi, M., Wada, Y., Sato, M., Takahara, J., Kawanishi, K. (1997) Effect of continuous intravenous injection of interleukin-6 and pretreatment with cyclooxygenase inhibitor on brain c-fos expression in the rat. Neuroendocrinology 66:47-53.
120. Nikkhah, G., Brandis, A. (1995) [Neurotransplantation in Parkinson disease: experimental and clinical results of functional reconstruction of the dopaminergic system]. Zentralbl Neurochir 56:153-160.
121. Nutt, J. G. 1992. Dyskinesia induced by levodopa and dopamine agonists in patients with Parkinson's disease. In Drug-induced movement disorders (A. E. Lang, and W. J Weiner, Eds.), pp. 281-314. Futura Publishing Co., Inc., Mount Kisko.
122. Olanow, C.W., Freeman, T.,Kordower, J. (2001) Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 345:146; author reply 147.
123. Olanow, C. W., Goetz, C. G., Kordower, J. H., Stoessl, A. J., Sossi, V., Brin, M. F., Shannon, K. M., Nauert, G. M., Perl, D. P., Godbold, J., Freeman, T. B. (2003) A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 54:403-414.
124. Olanow, C. W., Obeso, J. A. (2000) Preventing levodopa-induced dyskinesias. Ann Neurol 47:S167-176; discussion S176-168.
125. Perlow, M. J., Freed,W. J., Hoffer, B. J., Seiger, A., Olson, L.,Wyatt, R. J. (1979) Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. Science 204:643-647.
126. Peschanski, M., Defer, G., N'Guyen, J. P., Ricolfi, F., Monfort, J. C., Remy, P., Geny, C., Samson, Y., Hantraye, P., Jeny, R., Gaston, A., Kéravel, Y., Degos, J. D., and Cesaro, P. (1994). Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon. Brain 117 (Pt 3):487-499.
127. Peschanski, M., Dunnett, S. B. (2002) Cell therapy for Huntington's disease, the next step forward. Lancet Neurol 1:81.
128. Pfeiffer, C.,Wagner, M. L. (1994) Clozapine therapy for Parkinson's disease and other movement disorders. Am J Hosp Pharm 51:3047-3053.
129. Piccini, P. (2002) Dyskinesias after transplantation in Parkinson's disease. Lancet Neurol 1:472.
130. Piccini, P., Brooks, D. J., Björklund, A., Gunn, R. N., Grasby, P. M., Rimoldi, O., Brundin, P., Hagell, P., Rehncrona, S., Widner, H., Lindvall, O. (1999) Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat Neurosci 2:1137-1140.
131. Piccini, P., Weeks, R. A., Brooks, D. J. (1997) Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias. Ann Neurol 42:720-726.
132. Piccini, P., Pavese, N., and Brooks, D. J. (2003). Endogenous dopamine release after pharmacological challenges in Parkinson's disease. Ann Neurol 53: 647-653.
133. Piccini, P., Pavese, N., Hagell, P., Reimer, J., Björklund, A., Oertel, W. H., Quinn, N. P., Brooks, D. J., and Lindvall, O. (2005). Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain 128: 2977-2986.
134. Picconi, B., Centonze, D., Hakansson, K., Bernardi, G., Greengard, P., Fisone, G., Cenci, M. A., Calabresi, P. (2003) Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 6:501-506.
135. Quinn, N., Critchley, P., Marsden, C. D. (1987) Young onset Parkinson's disease. Mov Disord 2:73-91.
136. Quinn, N. P. (1998) Classification of fluctuations in patients with Parkinson's disease. Neurology 51:S25-29.
137. Rascol, O. (1999) L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: a clinical pharmacologic approach. Mov Disord 14 Suppl 1:19-32.
138. Rascol, O. (2000) Medical treatment of levodopa-induced dyskinesias. Ann Neurol 47:S179-188.
139. Rehncrona, R. (1997) A critical review of the current status and possible developments in brain transplantation. Adv Techn Standards in Neurosurg 23:3-46.
140. Reum, T., Olshausen, F., Mazel, T., Vorisek, I., Morgenstern, R., Sykova, E. (2002) Diffusion parameters in the striatum of rats with 6-hydroxydopamine-induced lesions and with fetal mesencephalic grafts. J Neurosci Res 70: 680-693.
141. Rice, M. E., Cragg, S. J., Greenfield, S. A. (1997) Characteristics of electrically evoked somatodendritic dopamine release in substantia nigra and ventral tegmental area in vitro. J Neurophysiol 77:853-862.
142. Rinne, U. K., Laihinen, A., Rinne, J. O., Nagren, K., Bergman, J., Ruotsalainen, U. (1990) Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease. Mov Disord 5:55-59.
143. Rioux, L., Gaudin, D. P., Bui, L. K., Gregoire, L., DiPaolo, T., Bedard, P. J. (1991) Correlation of functional recovery after a 6-hydroxydopamine lesion with survival of grafted fetal neurons and release of dopamine in the striatum of the rat. Neuroscience 40:123-131.
144. Rosin, A. J. (1978) Treatment of dyskinetic and choreatic movement disorders in adults. Gerontology 24: 46-57.
145. Rothwell, N. J., Hopkins, S. J. (1995) Cytokines and the nervous system II: Actions and mechanisms of action. Trends Neurosci 18:130-136.
146. Sauer, H., Brundin, P. (1991) Effects of cool storage on survival and function of intrastriatal ventral mesencephalic grafts. Rest. Neurol. Neuroscience 2:123-135.
147. Savasta, M., Mennicken, F., Chritin, M., Abrous, D. N., Feuerstein, C., Le Moal, M., Herman, J. P. (1992) Intrastriatal dopamine-rich implants reverse the changes in dopamine D2 receptor densities caused by 6-hydroxydopamine lesion of the nigrostriatal pathway in rats: an autoradiographic study. Neuroscience 46:729-738.
148. Schneider, J. S. (1989) Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage. Pharmacol Biochem Behav 34:193-196.
149. Schultzberg, M., Dunnett, S. B., Björklund, A., Stenevi, U.,
150. Smith, A. D., Bolam, J. P. (1990) The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones. Trends Neurosci 13:259-265.
151. Steece-Collier, K., Collier, T. J., Danielson, P. D., Kurlan, R., Yurek, D. M., Sladek, J. R. (2003) Embryonic mesencephalic grafts increase levodopa-induced forelimb hyperkinesia in parkinsonian rats. Mov Disord 18:1442-1454.
152. Stewart, P. (1898) Paralysis agitans; with an account of a new symptom. Lancet 2:1258-1260.
153. Stocchi, F., Ruggieri, S., Vacca, L., Olanow, C.W. (2002) Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. Brain 125:2058-2066.
154. Strecker, R. E., Sharp, T., Brundin, P., Zetterstrom, T., Ungerstedt, U., Björklund, A. (1987) Autoregulation of dopamine release and metabolism by intrastriatal nigral grafts as revealed by intracerebral dialysis. Neuroscience 22:169-178.
155. Stromberg, I., Kehr, J., Andbjer, B., Fuxe, K. (2000) Fetal ventral mesencephalic grafts functionally reduce the dopamine D2 receptor supersensitivity in partially dopamine reinnervated host striatum. Exp Neurol 164:154-165.
156. Studer, L., Tabar, V., McKay, R. D. (1998) Transplantation of expanded mesencephalic precursors leads to recovery in parkinsonian rats. Nat Neurosci 1:290-295.
157. Tchelingerian, J. L., Le Saux, F., Pouzet, B., Jacque, C. (1997) Widespread neuronal expression of c-Fos throughout the brain and local expression in glia following a hippocampal injury. Neurosci Lett 226:175-178.
158. Tel, B. C., Zeng, B. Y., Cannizzaro, C., Pearce, R. K., Rose, S., Jenner, P. (2002) Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets. Neuroscience 115:1047-1058.
159. Turner, D. A., Shetty, A. K. (2003) Clinical prospects for neural grafting therapy for hippocampal lesions and epilepsy. Neurosurgery 52:632-644; discussion 641-634.
160. Wenning, G. K., Odin, P., Morrish, P., Rehncrona, S., Widner, H., Brundin, P., Rothwell, J. C., Brown, R., Gustavii, B., Hagell, P., Jahanshahi, M., Sawle, G., Björklund, A., Brooks, D. J., Marsden, C. D., Quinn, N. P., Lindvall, O. (1997) Short-and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Ann Neurol 42:95-107.
161. Widner, H., Defer, G. L. (1999) Dyskinesias assessment: from CAPIT to CAPSIT. Core Assessment Program for Intracerebral Transplantations. Core Assessment Program for Surgical Interventional Therapies. Mov Disord 14 Suppl 1:60-66.
162. Widner, H., Tetrud, J., Rehncrona, S., Snow, B., Brundin, P., Gustavii, B., Björklund, A., Lindvall, O., Langston, J.W. (1992) Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). N Engl J Med 327:1556-1563.
163. Winkler, C., Kirik, D., Björklund, A., Cenci, M. A. (2002) L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 10:165-186.
164. Zetterstrom, T., Brundin, P., Gage, F. H., Sharp, T., Isacson, O., Dunnett, S. B., Ungerstedt, U., Björklund, A. (1986) In vivo measurement of spontaneous release and metabolism of dopamine from intrastriatal nigral grafts using intracerebral dialysis. Brain Res 362:344-349.
165. Zhou, J., Bradford, H. F., Stern, G. M. (1994) The response of human and rat fetal ventral mesencephalon in culture to the brain-derived neurotrophic factor treatment. Brain Res 656:147-156.